Phase 1b/2a Program Commences for RVX-208
News Aug 26, 2008
RVX-208, a novel small molecule therapeutic that facilitates endogenous
ApoA-I production. Dr. Allan Gordon, Senior Vice President Clinical Development of Resverlogix stated "We are very excited about moving forward into this important 28-daystudy with RVX-208. Our previous clinical study demonstrated that RVX-208 was safe, tolerable and had favorable pharmacokinetics,"
"This trial will continue to examine safety and tolerance as well it is a proof of principle study for ApoA-I production and HDL functionality. Approximately half of the subjects will have low levels of HDL cholesterol, a condition associated with
significant increased risk of cardiovascular disease," added Dr. Gordon.
"The ensuing Phase 1b/2a study comprises several novel facets to expedite
the clinical process for RVX-208 and its eventual registration as a drug,"
stated Donald J. McCaffrey, President and CEO of Resverlogix. McCaffrey
further confirmed, "Along with the required regulatory provisions that must be
addressed such as safety, tolerance and pharmacokinetics, the study also will
measure key reverse cholesterol transport markers which RVX-208 impacts. These are exclusive favorable features that make this drug unique among its
RVX-208 is positioned to be one of the most promising emerging
drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase
ApoA-I production and thereby raise HDL levels thus enhancing HDL
functionality to augment reverse cholesterol transport.